IntraGel and UroGen sign oncology collaboration with $7 million investment and global licensing options
- nuaxia
- 20 ore fa
- Tempo di lettura: 3 min
The agreements give UroGen access to IntraGel's sustained-release drug delivery platform while supporting development of the Phase II-ready cancer therapy TumoCure through an equity investment and future licensing options.
IntraGel Therapeutics and UroGen Pharma have entered into a strategic Option and Research License Agreement alongside a related equity investment agreement, under which UroGen will invest up to $7 million in IntraGel and receive an exclusive option to license worldwide rights to TumoCure following completion of its Phase II clinical study. The collaboration also gives UroGen research access to IntraGel's proprietary SRGel sustained-release platform, with options to license up to three additional oncology programmes based on the technology.
Field | Content |
Alert Type | Deal |
Companies | IntraGel Therapeutics; UroGen Pharma Ltd. |
Deal Type | Strategic collaboration, option and research licence agreement, and equity investment |
Asset or Company | TumoCure and the SRGel sustained-release drug delivery platform |
Therapy Area(s) | Oncology; Head and Neck Cancer |
Technology or Modality | Biodegradable sustained-release drug delivery platform (SRGel); localised oncology therapies |
Deal Value | UroGen will invest up to $7 million in IntraGel through an equity investment agreement. Financial terms relating to the option and potential worldwide licences were not disclosed. UroGen also receives an exclusive option to acquire worldwide rights to TumoCure following completion of its Phase II study, together with options to license up to three additional oncology products based on the SRGel platform. (UroGen Pharma, Ltd) |
Development Stage | Phase II-ready (TumoCure) |
Geography | Worldwide |
What Happened | On 20 August 2026, IntraGel Therapeutics and UroGen Pharma announced a strategic collaboration comprising an Option and Research License Agreement and a related equity investment agreement. UroGen will invest up to $7 million to support the Phase II clinical development of TumoCure, an investigational sustained-release therapy for advanced head and neck cancer. The agreement also grants UroGen research access to IntraGel's proprietary SRGel platform and exclusive options to obtain worldwide licences for TumoCure and up to three additional oncology programmes. (UroGen Pharma, Ltd) |
Why It Matters | The collaboration combines financing with strategic access to a drug delivery platform that could support multiple localised oncology therapies. For IntraGel, the investment supports clinical development while creating a pathway to commercialisation through an established oncology company. For UroGen, the agreement expands both its oncology pipeline and its sustained-release technology capabilities. (UroGen Pharma, Ltd) |
Supporting Context | SRGel is a biodegradable sustained-release formulation technology designed to deliver prolonged local drug exposure within solid tumours. TumoCure, the platform's lead investigational product, is being developed for advanced head and neck cancer using a sustained-release formulation of cisplatin intended to maximise local activity while limiting systemic exposure. (UroGen Pharma, Ltd) |
Strategic Rationale | UroGen gains access to a novel sustained-release technology platform with applications beyond a single product, while IntraGel secures funding and a commercial partner capable of advancing both TumoCure and future SRGel-based oncology programmes. (UroGen Pharma, Ltd) |
Potential Impact | If TumoCure progresses successfully through Phase II and UroGen exercises its licensing option, the collaboration could broaden UroGen's oncology portfolio while validating SRGel as a platform for localised treatment of solid tumours. The broader value of the partnership will depend on clinical outcomes and future option exercises. (UroGen Pharma, Ltd) |
Key Takeaway | The collaboration gives UroGen strategic access to both a Phase II-ready oncology programme and a sustained-release drug delivery platform while providing IntraGel with development funding and future commercialisation opportunities. |
What to Watch | Completion of the Phase II TumoCure study, any decision by UroGen to exercise its worldwide licensing option, and progression of additional SRGel-based oncology programmes. (UroGen Pharma, Ltd) |
Primary Source | |
Relevant Date | 20 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti